Shahman Shahab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shahman Shahab has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chandler O'LEary
Center for Phage Technology, Texas A&M University, College Station, Texas, USA
3 shared publications Avery Love
2 shared publications- Avery Love
Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publication Diann Gaalema
Department of Cardiology, The University of Texas Medical Branch (UTMB), Galveston, Texas, USA
1 shared publication- Esosa Odigie-Okon
Department of Cardiology, University of Texas Medical Branch, Galveston, TX 77755, USA
1 shared publication Khaled Alabdallah
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use Following Recent Hospitalization for Heart Failure With Preserved Ejection Fraction
BackgroundGlucagon-like peptide-1 receptor agonists improve symptoms and functional status in obesity-related heart failure with preserved ejection fraction, but outcomes after recent hospitalization remain uncertain. This study aims to evaluate associations between glucagon-like peptide-1 receptor agonist use and outcomes after hospitalization for acute heart failure with preserved ejection fraction.MethodsWe conducted a retrospective cohort study using the TriNetX Collaborative Network in the United States. Women and men with heart failure with preserved ejection fraction and overweight or obesity were included after first-hospitalization for acute or acute-on-chronic diastolic heart failure. Propensity score matching balanced demographics, comorbidities, and cardiovascular medications. Outcomes were assessed from 90 days after index through 1 and 5 years.ResultsAfter matching, each cohort included 893 patients at 1 year and 663 at 5 years. Glucagon-like peptide-1 receptor agonists use was not associated with lower 1-year heart failure with preserved ejection fraction hospitalization (hazard ratio 0.99, 95% confidence interval 0.78 to 1.25; p = 0.93) or all-cause hospitalization (hazard ratio 0.92, 95% confidence interval 0.75 to 1.11; p = 0.37). Mortality was numerically lower at 1 year (hazard ratio 0.68, 95% confidence interval 0.46 to 1.02; p = 0.058) and lower at 5 years (hazard ratio 0.72, 95% confidence interval 0.53 to 0.97; p = 0.032).ConclusionsUse after hospitalization was not associated with fewer recurrent exacerbations or hospitalizations but was associated with lower long-term mortality. The finding is hypothesis-generating.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use Following Recent Hospitalization for Heart Failure With Preserved Ejection Fraction
BackgroundGlucagon-like peptide-1 receptor agonists improve symptoms and functional status in obesity-related heart failure with preserved ejection fraction, but outcomes after recent hospitalization remain uncertain. This study aims to evaluate associations between glucagon-like peptide-1 receptor agonist use and outcomes after hospitalization for acute heart failure with preserved ejection fraction.MethodsWe conducted a retrospective cohort study using the TriNetX Collaborative Network in the United States. Women and men with heart failure with preserved ejection fraction and overweight or obesity were included after first-hospitalization for acute or acute-on-chronic diastolic heart failure. Propensity score matching balanced demographics, comorbidities, and cardiovascular medications. Outcomes were assessed from 90 days after index through 1 and 5 years.ResultsAfter matching, each cohort included 893 patients at 1 year and 663 at 5 years. Glucagon-like peptide-1 receptor agonists use was not associated with lower 1-year heart failure with preserved ejection fraction hospitalization (hazard ratio 0.99, 95% confidence interval 0.78 to 1.25; p = 0.93) or all-cause hospitalization (hazard ratio 0.92, 95% confidence interval 0.75 to 1.11; p = 0.37). Mortality was numerically lower at 1 year (hazard ratio 0.68, 95% confidence interval 0.46 to 1.02; p = 0.058) and lower at 5 years (hazard ratio 0.72, 95% confidence interval 0.53 to 0.97; p = 0.032).ConclusionsUse after hospitalization was not associated with fewer recurrent exacerbations or hospitalizations but was associated with lower long-term mortality. The finding is hypothesis-generating.
- Open Access
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105656
Improving Patient Access and Scanning Efficiency in Cardiovascular Magnetic Resonance
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105656
Open AccessImproving Patient Access and Scanning Efficiency in Cardiovascular Magnetic Resonance
- Open Access
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Coronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Open AccessCoronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.